Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection

Uriel Sandkovsky, Susan Swindells, Brian L. Robbins, Sarah R. Nelson, Edward P. Acosta, Courtney V Fletcher

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Paired plasma and intracellular samples were obtained from 12 HIV-infected adults taking raltegravir twice daily (b.i.d.), and after switching to once daily. With b.i.d. dosing, no plasma trough concentrations were below the IC95, in contrast to 33% for once daily dosing. Fifty percent of the once daily group had intracellular trough concentrations below the inhibitory concentration 95 (IC95), 25% in the b.i.d. group. Lower plasma and intracellular concentrations may contribute to inferior virologic suppression rates observed with once daily raltegravir dosing.

Original languageEnglish (US)
Pages (from-to)2257-2259
Number of pages3
JournalAIDS
Volume26
Issue number17
DOIs
StatePublished - Nov 13 2012

Fingerprint

HIV Infections
HIV
Raltegravir Potassium

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection. / Sandkovsky, Uriel; Swindells, Susan; Robbins, Brian L.; Nelson, Sarah R.; Acosta, Edward P.; Fletcher, Courtney V.

In: AIDS, Vol. 26, No. 17, 13.11.2012, p. 2257-2259.

Research output: Contribution to journalArticle

Sandkovsky, Uriel ; Swindells, Susan ; Robbins, Brian L. ; Nelson, Sarah R. ; Acosta, Edward P. ; Fletcher, Courtney V. / Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection. In: AIDS. 2012 ; Vol. 26, No. 17. pp. 2257-2259.
@article{dbeb7d5b593c40ca9b77331d433ff8cb,
title = "Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection",
abstract = "Paired plasma and intracellular samples were obtained from 12 HIV-infected adults taking raltegravir twice daily (b.i.d.), and after switching to once daily. With b.i.d. dosing, no plasma trough concentrations were below the IC95, in contrast to 33{\%} for once daily dosing. Fifty percent of the once daily group had intracellular trough concentrations below the inhibitory concentration 95 (IC95), 25{\%} in the b.i.d. group. Lower plasma and intracellular concentrations may contribute to inferior virologic suppression rates observed with once daily raltegravir dosing.",
author = "Uriel Sandkovsky and Susan Swindells and Robbins, {Brian L.} and Nelson, {Sarah R.} and Acosta, {Edward P.} and Fletcher, {Courtney V}",
year = "2012",
month = "11",
day = "13",
doi = "10.1097/QAD.0b013e328359a978",
language = "English (US)",
volume = "26",
pages = "2257--2259",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "17",

}

TY - JOUR

T1 - Measurement of plasma and intracellular concentrations of raltegravir in patients with HIV infection

AU - Sandkovsky, Uriel

AU - Swindells, Susan

AU - Robbins, Brian L.

AU - Nelson, Sarah R.

AU - Acosta, Edward P.

AU - Fletcher, Courtney V

PY - 2012/11/13

Y1 - 2012/11/13

N2 - Paired plasma and intracellular samples were obtained from 12 HIV-infected adults taking raltegravir twice daily (b.i.d.), and after switching to once daily. With b.i.d. dosing, no plasma trough concentrations were below the IC95, in contrast to 33% for once daily dosing. Fifty percent of the once daily group had intracellular trough concentrations below the inhibitory concentration 95 (IC95), 25% in the b.i.d. group. Lower plasma and intracellular concentrations may contribute to inferior virologic suppression rates observed with once daily raltegravir dosing.

AB - Paired plasma and intracellular samples were obtained from 12 HIV-infected adults taking raltegravir twice daily (b.i.d.), and after switching to once daily. With b.i.d. dosing, no plasma trough concentrations were below the IC95, in contrast to 33% for once daily dosing. Fifty percent of the once daily group had intracellular trough concentrations below the inhibitory concentration 95 (IC95), 25% in the b.i.d. group. Lower plasma and intracellular concentrations may contribute to inferior virologic suppression rates observed with once daily raltegravir dosing.

UR - http://www.scopus.com/inward/record.url?scp=84869489324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869489324&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e328359a978

DO - 10.1097/QAD.0b013e328359a978

M3 - Article

C2 - 22948265

AN - SCOPUS:84869489324

VL - 26

SP - 2257

EP - 2259

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 17

ER -